This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 5 of 11 for:    nicvax

Antibody and Safety Study of 6 Doses of NicVAX in Smokers

This study has been completed.
Information provided by (Responsible Party):
Nabi Biopharmaceuticals Identifier:
First received: January 9, 2008
Last updated: May 8, 2012
Last verified: May 2012
Prior clinical trials examined several schedules of a nicotine vaccine (NicVAX) for anti-nicotine antibody responses, and their impact on helping smokers quit. The best schedule so far has been one with doses at weeks 0, 4, 8, 16 and 26. This new study tests whether changing the schedule to weeks 0, 4, 8, 12 and 16 is an improvement for stimulating antibodies to nicotine. Routine vaccine safety information is also collected. Amendment 1 adds a 6th dose at week 26, and extends follow-up through week 52.

Condition Intervention Phase
Smoking Biological: 3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®) Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Phase 2 Single Center, Open-label Study to Assess Immunogenicity and Safety of 6 Doses of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX®)in Smokers

Further study details as provided by Nabi Biopharmaceuticals:

Primary Outcome Measures:
  • Anti-nicotine antibody concentration [ Time Frame: 12 time points between screening and week 20 ]

Secondary Outcome Measures:
  • Vaccine reactogenicity [ Time Frame: for 7 days after each dose ]
  • Adverse events [ Time Frame: for 30 weeks after 1st dose (4 wk after last dose) ]

Enrollment: 74
Study Start Date: January 2008
Study Completion Date: October 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NicVAX Biological: 3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®)
1.0 ml injection IM given every 4 weeks (weeks 0, 4, 8, 12, 16)
Other Name: NicVAX
Experimental: NicVAX Lot 2
2nd cohort receives a different lot of vaccine from the 1st cohort
Biological: 3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®)
1.0 ml injection IM given every 4 weeks (weeks 0, 4, 8, 12, 16)
Other Name: NicVAX


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Healthy smoker, ≥10 cigarettes per day for 6 months, exhaled carbon monoxide ≥10 ppm
  • Written informed consent
  • Negative urine pregnancy test, and willing to use birth control during the study, if applicable

Exclusion Criteria:

  • Prior exposure to nicotine vaccine
  • Clinically significant allergic reactions, especially to components of the vaccine
  • Serious or unstable clinical disease within the past 6 months
  • Use of any smoking cessation therapy within 30 days preceding 1st dose
  • Immunosuppression, due to: steroids or other immunosuppressants in the last 30 days, history of cancer or cancer treatment in the last 60 months, known HIV infection, or congenital or acquired immunodeficiency
  • Use of any vaccine other than influenza vaccine within 30 days prior to each study dose
  • Use of another IND drug or device within 30 days preceding 1st dose
  • Inability to follow the protocol, or illicit drug use in the past 12 months, or psychiatric disorder in the past 3 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00598325

United States, Maryland
Accelovance, Inc.
Rockville, Maryland, United States, 20850
Sponsors and Collaborators
Nabi Biopharmaceuticals
Study Director: Matt Hohenboken, MD, PhD Nabi Biopharmaceuticals
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Nabi Biopharmaceuticals Identifier: NCT00598325     History of Changes
Other Study ID Numbers: Nabi-4513
Study First Received: January 9, 2008
Last Updated: May 8, 2012

Keywords provided by Nabi Biopharmaceuticals:

Additional relevant MeSH terms:
Immunologic Factors
Physiological Effects of Drugs processed this record on September 19, 2017